Verkazia® (cyclosporine ophthalmic emulsion) 0.1% is now available for the treatment of vernal keratoconjunctivitis in children and adults.
Vernal keratoconjunctivitis is a rare allergic eye disease that results in severe inflammation of the surface of the eye. Verkazia is an oil-in-water cationic emulsion that works by inhibiting T-cell activation and reducing the level of immune cells and mediators.
The approval was based on data from 2 randomized, double-masked, vehicle-controlled trials, VEKTIS (ClinicalTrials.gov Identifier: NCT01751126) and NOVATIVE (ClinicalTrials.gov Identifier: NCT00328653), which evaluated the efficacy and safety of Verkazia in patients with severe vernal keratoconjunctivitis or moderate to severe vernal keratoconjunctivitis, respectively.
Results from both trials showed that treatment with Verkazia improved inflammation of the cornea and ocular itching. The most common adverse reactions reported were eye pain (12%) and eye pruritus (8%), which were usually transitory and occurred during instillation.
Verkazia is supplied in single-dose vials (0.3mL) in 30-, 60-, or 120-count boxes. The emulsion from an individual single-dose vial should be used immediately after opening for administration to 1 or both eyes; the remaining contents should be discarded immediately after administration.
- Santen’s Verkazia® (cyclosporine ophthalmic emulsion) 0.1% now available for the treatment of vernal keratoconjunctivitis in children and adults in the United States. News release. Santen Inc. Accessed May 2, 2022. https://www.businesswire.com/news/home/20220502005078/en/Santen%E2%80%99s-Verkazia%C2%AE-Cyclosporine-Ophthalmic-Emulsion-0.1-Now-Available-for-the-Treatment-of-Vernal-Keratoconjunctivitis-in-Children-and-Adults-in-the-United-States
- Verkazia. Package insert. Santen Inc.; 2022. Accessed May 2, 2022. https://www.verkazia.com/pdf/Verkazia-PI.pdf